期刊文献+

经皮冠状动脉介入治疗患者应用普通肝素和低分子肝素对血浆肝细胞生长因子水平的影响 被引量:1

Effect of unfractioned heparin and low molecular weight heparin on expression of plasma hepatocyte growth factor in patients with unstable angina pectoris who undergo percutaneous coronary intervention
暂未订购
导出
摘要 目的探讨不稳定型心绞痛患者经皮冠状动脉介入治疗(PCI)术中分别静脉应用普通肝素或低分子肝素对血浆肝细胞生长因子(HGF)的影响。方法74例不稳定型心绞痛患者根据PCI术时使用肝素类型分为普通肝素组(49例)和低分子肝素组(25例),分别在术前、术中、术后即刻以ELISA法测定外周血HGF的水平。结果两组术前HGF水平差异无统计学意义。普通肝素组和低分子肝素组术中及术后即刻HGF水平与术前相比均显著升高(术后中与术前比较:普通肝素组为12322.19±3723.31ng/L比1736.09±603.95ng/L,P<0.00001;低分子肝素组为9141.31±2521.91ng/L比1675.28±630.53ng/L,P<0.00001。术后即刻与术前HGF水平比较:普通肝素组为13565.60±3768.99ng/L比1736.09±603.95ng/L,P<0.00001;低分子肝素组为10092.35±2723.00ng/L比1675.28±630.53ng/L,P<0.00001)。低分子肝素组在PCI术中和术后即刻两个不同时段其外周血HGF水平均低于普通肝素组(P均<0.01)。结论不稳定型心绞痛患者在PCI术中无论是应用普通肝素还是低分子肝素,均可促进外周血HGF的释放,但在PCI术手术过程中,静脉注射普通肝素升高外周血HGF的作用比低分子肝素更强。 Objective To investigate the effect of unfractioned heparin and low molecular weight heparin on expression of plasma hepatocyte growth factor (HGF) during percutaneous coronary intervention (PCI). Methods Seventy four patients with unstable angina pectoris were classfied into unfractioned heparin (UFH) group ( n = 49) and low molecular weight heparin ( LMWH ) group ( n = 25 ) according to the type of heparin used during PCI. The plasma levels of HGF were measured before, during, and after PCI in the patients. Results The plasma levels of HGF before procedure were of no statistical difference between the two groups. The levels of HGF were significantly increased during and after PCI in the unfractioned heparin and the LMWH group. Comparing with the pre-procedure level, the post-procedure level of HGF in the UFH group was 13 565.60 ±3 768.99 ng/L (vs 1 736. 09 ±603.95 ng/L, P 〈 O. 000 O1 ) and in the LMWH group, it was 10 092. 35 ± 2 723. 00 ng/L ( vs 1 675. 28 ± 630. 53 ng/L, P 〈 0. 000 01 ) respeetively. However, the HGF levels were lower in the LMWH group both during and after the procedure compared with the UFH group (9 141.31 ±2 521.91 ng/L vs 12 322. 19 ±3 723. 31 ng/L, P 〈0.01 and 10 092. 35 ± 2 723.00 ng/L vs 13 565.60 ±3 768. 99 ng/L, P 〈 O. O1 respectively). Conclusion There is an enhaneed expression of hepatocyte growth factor in patients with unstable angina pectoris during PCI using LMWH or UFH. Intravenous UFH can induce greater elevation in the plasma HGF level than intravenous LMWH in patients with unstable angina pectoris during PCI.
出处 《中国介入心脏病学杂志》 2007年第3期154-157,共4页 Chinese Journal of Interventional Cardiology
基金 浙江省医药卫生科学研究基金(2004B163) 市医药卫生科技重点项目(2003J003)
关键词 冠状动脉疾病 肝细胞生长因子 血管成形术 经腔 经皮冠状动脉 肝素 Coronary artery disease Hepatocyte growth factor Angioplasty, transluminal, Heparin
  • 相关文献

参考文献16

  • 1Nakagami H,Morishita R,Yamamoto K,et al.Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK,STAT3,and AKT in endothelial cells.Hypertension,2001,37:581-586.
  • 2Nakagami H,Morishita R,Yamamoto K,et al.Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells.J Hypertens,2000,18:1411-1420.
  • 3Heeschen C,Dimmeler S,Hamm CW,et al.Prognostic Significance of Angiogenic Growth Factor Serum Levels in Patients With Acute Coronary Syndromes.Circulation,2003,107:524-530.
  • 4Susen S,Sautiere K,Mouquet F,et al.Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization.Eur Heart J,2005,26:2387-2395.
  • 5Salbach PB,Bruckmann M,Turovets O,et al.Heparin-mediated selective release of hepatocyte growth factor in humans.Br J Clin Pharmacol,2000,50:221-226.
  • 6不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量:2699
  • 7Bhatt DL,Lee BI,Casterella PJ,et al.Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention:results of the coronary revascularization using integrilin and single bolus enoxaparin study.J Am Coll Cardiol,2003,41:20-25.
  • 8Galeote G,Hussein M,Sobrino N,et al.Use of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions:a randomized pilot study.Rev Esp Cardiol,2002,55:1261-1266.
  • 9Matsumori A,Ono K,Okada M,et al.Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin.J Mol Cell Cardiol,1998,30:2145-2149.
  • 10Naka D,Ishii T,Shimomura T,et al.Heparin modulates the receptor-binding and mitogenic activity of hepatocytegrowth factor on hepatocytes.Exp Cell Res,1993,209:317-324.

共引文献2698

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部